Skip to main content
UTHR logo

UTHR · UNITED THERAPEUTICS Corp

Track UTHR — free
$499.73 -1.54 (-0.31%) At close · Aug 14
Market Cap
$21.43B
Shares
42.89M

Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.

Filed Seller Shares
2026-08-06 PAUL MAHON 8,300
2026-08-03 MARTINE ROTHBLATT 199,500
2026-07-16 PAUL A. MAHON 8,300
2026-07-10 JAN MALCOLM 325
2026-07-02 PAUL MAHON 8,300
2026-07-01 MARTINE ROTHBLATT 209,000
2026-06-18 PAUL MAHON 8,300
2026-06-04 PAUL MAHON 8,300
2026-06-01 MARTINE ROTHBLATT 199,500
2026-05-21 PAUL MAHON 8,300
2026-05-12 NILDA MESA 258
2026-05-07 PAUL MAHON 8,300
2026-05-04 JAMES C EDGEMOND 148,750
2026-05-01 MARTINE ROTHBLATT 190,000
2026-04-24 CHRISTOPHER PATUSKY 2,910
2026-04-17 CHRISTOPHER PATUSKY 1,000
2026-04-16 PAUL MAHON 8,300
2026-04-02 PAUL MAHON 8,300
2026-04-01 MARTINE ROTHBLATT 199,500
2026-03-30 CHRISTOPHER CAUSEY 1,300
2026-03-26 TOMMY THOMPSON 2,000
2026-03-23 JUDY OLIAN 200
2026-03-23 JAMES C EDGEMOND 120,000
2026-03-19 PAUL MAHON 8,300
2026-03-17 JAN MALCOLM 45
2026-03-16 JUDY OLIAN 200
2026-03-09 JUDY OLIAN 200
2026-03-05 PAUL MAHON 8,300
2026-03-04 RAYMOND KURZWEIL 4,910
2026-03-04 CHRISTOPHER CAUSEY 20
2026-03-04 TOMMY THOMPSON 2,000
2026-03-03 JAN MALCOLM 50
2026-03-02 JUDY OLIAN 200
2026-03-02 MARTINE ROTHBLATT 209,000
2026-02-25 CHRISTOPHER CAUSEY 1,000
2026-02-19 PAUL MAHON 8,300
2026-02-17 JAN MALCOLM 50
2026-02-05 PAUL MAHON 8,300
2026-02-03 JAN MALCOLM 50
2026-02-02 Michael Benkowitz 90,000
2026-01-20 JAN MALCOLM 50
2026-01-15 PAUL MAHON 8,300
2026-01-06 JAN MALCOLM 50
2026-01-06 CHRISTOPHER CAUSEY 1,000
2026-01-05 Michael Benkowitz 90,000
2026-01-02 PAUL MAHON 8,300
2026-01-02 CHRISTOPHER CAUSEY 1,000
2025-12-29 PAUL MAHON 11,000
2025-12-22 LOUIS WADE SULLIVAN REVOCABLE TRUST 5,950
2025-12-19 ROTHBLATT MARTINE A 2,000
Showing 1–50 of 242 filings
Key facts CIK 1082554 CUSIP 91307C102 13F (30d) 806 filings 786 filers Visit website Investor relations